Novartis "Relieve"
We are assessing the effectiveness and safety of remibrutinib, an investigational medicine being developed for people who have generalized Myasthenia Gravis (gMG).
Inclusion Criteria:
– Have a confirmed, documented diagnosis of gMG: either positive for AChR+ antibody or MuSK+ antibody, or seronegative for both AChR and MuSK antibodies at screening.
– Are able to safely swallow the study medication.
– Between the ages of 18-75.
– Take stable, standard-of-care (SOC) Myasthenia Gravis medication prescribed by your treating physician.
– Note: You must continue to take
your regular gMG medication
for the duration of the study.
